Business
UPDATE CANCER PROGRAMME IPP-204106
UPDATE CANCER PROGRAMME IPP-204106.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 5073L Immupharma PLC 13 August 2013 \n\n \n\n\n\n\nFOR IMMEDIATE RELEASE\n\n\n13 AUGUST 2013\n\n\n\n\n\n\n\n\n\n\n\n\n \nImmuPharma plc\n \nUPDATE\nCANCER PROGRAMME IPP-204106\n \nImmuPharma plc (LSE:IMM) (\"Immupharma\" or the \"Company\" or the \"Group\"), the specialist drug discovery and development company is pleased to provide an update on its lead cancer programmeIPP-204106.\n \nAs announced in September last year the Company commenced dosing in cancer patients with the next generation of the \"polyplexed Nucant\" (See notes to editors).\nThree hospitals are conducting these trials designed to assess safety and dosing levels in Europe including the prestigious Institute Jules Bordet, an Integrated Multidisciplinary Centre which is the only autonomous hospital in Belgium totally dedicated to cancer. \nThe trial is progressing according to protocol and its objective is to identify the optimal dose for treating patients. The oncologists involved in the study are leading the decisions on the number of patients and the dosing regimen. Patients that are being enrolled in this trial are in a serious condition, suffering from a range of cancers, all have metastasis (tumour spreading) and have failed their previous treatment. This trial will be followed by a Phase II efficacy study designed to treat various cancers, in approximately 30 patients, to identify appropriate biomarkers. \nOur further intention is to conduct more focused follow-up studies on patients with glioblastoma (brain tumour), metastatic melanoma, and pancreatic cancer where nucleolin plays a key role and who are showing the appropriate biomarkers. \n \nDr Robert Zimmer, MD, PhD, ImmuPharma's President and Chief Scientific Officer commented:\"The clinical development of our cancer programme continues to be a key priority for ImmuPharma. We look forward to announcing interim results from the current trial in the near future.\"\n \n \n For further information please contact:\n \n\n\n\n\nImmuPharma PLC (www.immupharma.com)\n\n\n\n\n\n\n\nDr Robert Zimmer, President\n\n\n+33 389 66 13 20\n\n\n\n\nDimitri Dimitriou, Chief Executive Officer \n\n\n+44 20 7152 4080\n\n\n\n\nRichard Warr, Chairman\n\n\n+44 20 7152 4080\n\n\n\n\nLisa Baderoon, Head of Inve...